The Cambridge, Mass.-based drugmaker was developing revusiran for the treatment of hereditary amyloidosis with cardiomyopathy — a rare condition in which amyloid plaque collects in the organs and can cause heart failure, according to the report.
The company decided to suspend a Phase III trial of the drug after unblinded data from a previous trial “revealed an imbalance of mortality in the revusiran arm as compared to placebo,” according to a company statement.
Upon news of the halted drug development, Alnylam’s shares dropped more than 40 percent to $40.96 in post-market trading after closing at $70.30 on Wednesday.
More articles on supply chain:
FedEx to open new Ohio distribution center in 2017
Novartis restructures research unit, sheds 175 jobs: 4 things to know
Insmed buys AstraZeneca’s respiratory drug for $150M: 5 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
